AndroGel and Hormonal Contraceptives: Drug Interaction, Risks, and Clinical Guidance

AndroGel is a brand-name topical testosterone gel (1% and 1.62% formulations) approved by the FDA for testosterone replacement in adult men with hypogonadism. It is not indicated as, and does not function as, a contraceptive. Hormonal contraceptives include combined estrogen-progestin pills, patches, and rings, progestin-only pills, the etonogestrel implant, and hormonal IUDs. This page addresses two distinct clinical situations where these drug classes intersect: unintended secondary testosterone exposure in a female partner of a man using AndroGel, and concurrent use of testosterone gel and a hormonal contraceptive in the same patient, most often a transmasculine person.

The most load-bearing fact on this page: AndroGel carries an FDA boxed warning about secondary testosterone exposure to women and children through skin contact, this is a regulatory finding, not a modeled risk; by contrast, whether testosterone gel meaningfully blunts hormonal contraceptive efficacy through a pharmacokinetic or pharmacodynamic mechanism is biologically plausible but not established by controlled trial evidence, so no contraceptive method should be presumed protected, and none should be presumed defeated, on pharmacology alone.

Two different problems, not one interaction

These scenarios do not share a mechanism, and conflating them leads to the wrong precaution.

Secondary exposure happens when testosterone gel transfers from a treated man's skin to a partner's skin before the gel has fully dried and absorbed. This is a transfer-of-drug problem, not a drug-drug interaction in the pharmacological sense. It applies regardless of whether the partner uses any contraceptive at all.

Concurrent use in one patient happens when a person takes testosterone gel and a hormonal contraceptive at the same time, for example a transmasculine patient on gender-affirming testosterone who also needs pregnancy prevention or menstrual suppression. Here the question is whether testosterone changes contraceptive drug levels or opposes the contraceptive's mechanism.

Does testosterone interact with hormonal contraceptives at the level of drug metabolism?

Testosterone and ethinyl estradiol are both metabolized in part through the CYP3A4 pathway, and it is pharmacologically plausible that competitive enzyme binding could alter clearance of either drug when both are present. Topical testosterone from a gel largely bypasses first-pass hepatic metabolism, which is expected to blunt any CYP3A4-mediated effect compared with oral testosterone. Whether this produces a clinically meaningful pharmacokinetic change with AndroGel specifically has not been confirmed by a trial identified for this article, and any specific number describing the magnitude of that change should be treated as unverified until checked against the primary literature.

The more consistently described mechanism runs through sex hormone-binding globulin (SHBG). Exogenous testosterone is understood to lower SHBG. Since SHBG binds both testosterone and estradiol, a drop in SHBG can raise the free fraction of circulating ethinyl estradiol in a patient taking a combined contraceptive. A rise in free estrogen is a plausible contributor to estrogen-related side effects such as headache, nausea, or venous thromboembolism risk, but this page cannot confirm a specific quantified increase in clinical events from this mechanism alone, and it should not be presented to a patient as an established number.

Clinically, a stronger and better-documented pharmacokinetic concern is co-administration of either drug with a potent CYP3A4 inhibitor or inducer (examples: ketoconazole, ritonavir, certain anticonvulsants). Before attributing any lab or symptom change to the testosterone-contraceptive pairing, a full medication reconciliation for CYP3A4 modulators is the more useful first step.

Does testosterone gel block contraceptive effectiveness?

Combined hormonal contraceptives work mainly by suppressing ovulation through estrogen and progestin action on the hypothalamic-pituitary-gonadal axis, with additional effects on cervical mucus and endometrial lining. Progestin-only methods rely more heavily on the local cervical mucus and endometrial effects, with ovulation suppression varying by method.

Exogenous testosterone suppresses gonadotropins (LH and FSH) through negative feedback at the hypothalamus, and at replacement doses this suppression is substantial in men. In people with ovaries, testosterone-induced amenorrhea does not reliably mean anovulation. Case series in transmasculine patients on testosterone therapy have reported persistent ovarian follicular activity despite absent periods, though the specific proportion of patients affected in any one study should be verified against the primary paper rather than repeated as a fixed figure here.

The clinical implication accountable bodies have converged on is straightforward even without a precise ovulation-suppression percentage: testosterone therapy should not be relied on as contraception in a person who has a uterus, retains ovaries, and is sexually active with a partner who can cause pregnancy. This is a guideline-level recommendation from endocrinology and reproductive health bodies working in this space, and it holds independent of the exact mechanistic numbers, which is why it is treated as established here even though the underlying physiology is only partly quantified.

Secondary exposure: the risk with the clearest regulatory basis

Of the two problems described on this page, secondary dermal exposure has the strongest evidence base, because it comes directly from FDA safety review rather than from extrapolated pharmacology.

The FDA-approved label for AndroGel includes a boxed warning describing secondary exposure to testosterone gel in women and children who have skin contact with a treated man's application site. The FDA has also issued safety communications addressing reports of virilization, including signs such as increased body hair, voice change, and clitoral enlargement, in women and children secondarily exposed to topical testosterone products based on FDA safety communications. These are regulatory findings based on postmarketing reports, not a controlled trial with a denominator, so an exact incidence rate should not be quoted as if it were known.

The FDA label recommends applying gel to skin that can be covered by clothing, washing hands with soap and water immediately after application, and either washing the application site or ensuring it is covered before anticipated skin-to-skin contact according to the current AndroGel prescribing information (version should be verified at time of use). Specific transfer magnitudes reported in older studies (for example, exact serum testosterone changes in exposed partners after a stated number of minutes of contact) are not reproduced here because the underlying paper could not be independently verified for this draft; an editor with primary-literature access should confirm any such figure before it is published as a precise number.

If contraception subsequently fails and a female partner becomes pregnant while ongoing secondary testosterone exposure is occurring, or while a transmasculine patient is on testosterone and pregnancy is not desired, the FDA labels testosterone as contraindicated in pregnancy because of the risk of virilization of a female fetus. This is a labeled contraindication, not a modeled risk, and it is one of the strongest reasons secondary-exposure precautions and reliable contraception are both taken seriously in practice.

Choosing a contraceptive method during testosterone therapy

For a patient using testosterone gel who also needs a contraceptive, method choice can reduce the theoretical pharmacodynamic conflict described above, based on how each method works rather than on head-to-head trial data against testosterone specifically.

Progestin-only intrauterine devices and the subdermal etonogestrel implant work mainly through local effects on the endometrium and cervical mucus, plus a systemic progestin effect for the implant, and their contraceptive action does not depend on suppressing the same hypothalamic-pituitary-gonadal axis that testosterone also acts on. Guidance from the CDC's U.S. Medical Eligibility Criteria for Contraceptive Use addresses safe contraceptive selection across many medical conditions and is a reasonable starting reference for method eligibility generally, though it was not written specifically for concurrent testosterone therapy (CDC MMWR, U.S. MEC for Contraceptive Use, 2016).

Combined oral contraceptives are generally considered a less favorable choice in this context, both because ongoing testosterone use may lower SHBG and raise free ethinyl estradiol by the mechanism described above, and because many transmasculine patients already carry standard contraindications to estrogen-containing methods (for example, migraine with aura) independent of testosterone use.

Depot medroxyprogesterone acetate is another progestin-only option; its main established drawback is a reduction in bone mineral density with long-term use, which is a labeled consideration separate from any testosterone interaction and should be discussed on its own terms.

ACOG's committee opinion on care for transgender and gender-diverse individuals addresses contraceptive counseling in this population and is a relevant guideline-level source for method selection conversations (ACOG Committee Opinion No. 823).

Monitoring and counseling in practice

For a female partner of a man using AndroGel, monitoring is mainly behavioral rather than laboratory. Confirm the patient applies gel to a site that clothing can cover, washes hands immediately after application, and either avoids unprotected skin contact with the site for the interval stated on the label or ensures the site is washed first. If the partner develops new acne, unexpected hair growth, menstrual changes, or voice change, a serum total testosterone level in the partner is a reasonable next step, ordered by her own clinician.

For a patient using testosterone gel and a hormonal contraceptive concurrently, baseline and follow-up serum total and free testosterone, along with SHBG, are reasonable to track dose adequacy and any unexpected shifts, with follow-up intervals set by the prescribing clinician rather than a fixed schedule asserted here. A persistently high testosterone level in a patient who still has a uterus and ovaries is a prompt to revisit contraceptive adequacy directly with the patient, not to assume protection.

Counseling should be specific to the person in front of the clinician. A man starting AndroGel needs practical instructions on application site, clothing coverage, and hand-washing, plus a plain statement that a partner who is exposed and develops androgenic symptoms should be evaluated. A transmasculine patient needs a direct statement that testosterone alone should not be relied on as birth control, that missed or irregular periods do not confirm anovulation, and that a progestin-only IUD or implant is a common and reasonable choice if pregnancy prevention matters to them. Neither of these counseling points requires an exact statistic to be true or useful, and neither should be delivered with a numeric claim that has not been checked against a primary source.

What is established, what is plausible, and what remains unverified

When to involve a clinician or pharmacist directly

A pharmacist or prescriber should be consulted before assuming any of the above applies to a specific patient, particularly when: a female partner develops new androgenic symptoms; a transmasculine patient is considering stopping a contraceptive because periods have stopped; either patient is starting or stopping a strong CYP3A4 inhibitor or inducer; or a pregnancy is suspected in a partner with ongoing secondary testosterone exposure, which warrants urgent evaluation given the pregnancy contraindication on testosterone's label.

Common questions

Can AndroGel and hormonal contraceptives be used by the same household without special precautions? Not without precautions if a female partner will have skin contact with the application site. The FDA-recommended clothing coverage and hand-washing steps are the primary mitigation and are described on the product label.

Does testosterone gel count as birth control for a transmasculine patient? No. Guideline-level recommendations advise against relying on testosterone therapy alone for pregnancy prevention, because amenorrhea does not reliably indicate that ovulation has stopped.

Which contraceptive is preferred during testosterone therapy? Progestin-only IUDs and the subdermal implant are commonly preferred because their mechanism does not depend on the same hormonal axis that testosterone suppresses, though this is a guideline-consistent, mechanism-based preference rather than a head-to-head trial result specific to testosterone co-use.

What should a female partner do if she notices new hair growth or acne? She should have this evaluated by her own clinician, who may check a serum testosterone level, and secondary-exposure precautions with her partner's gel application should be reviewed.

References

3. Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65(3):1-103. https://www.cdc.gov/mmwr/volumes/65/rr/rr6503a1.htm
4. American College of Obstetricians and Gynecologists. Health care for transgender and gender diverse individuals. ACOG Committee Opinion No. 823. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2021/03/health-care-for-transgender-and-gender-diverse-individuals

Editor's note for review: this draft removed several specific numeric claims and one attributed direct quotation from the earlier version (exact serum-level transfer figures, a specific percentage of patients with persistent ovulation, and a quoted Endocrine Society guideline passage) because the underlying PubMed identifiers could not be verified against the actual papers during this pass. Before publication, a reviewer with primary-literature access should either confirm and reinstate those figures with correct citations, or confirm this narrower version is accurate as written.